At VestBio Capital we Connect the first-of-their-kind biotech impact companies with investors, through a professional capital management & first-class scientific team in a single company, thus being part of the evolution of the most promising companies in the world
Clinical Stage Therapeutic Drug Development Companies
World Class Biotech Companies
• Companies from the World’s Best Life Sciences Hubs: Boston & USA, UK, Switzerland.
• …with Excellent Management teams (i.e., Pfizer Ex-president, CEO with more than 7 IPOs with an average of x12,…).
• …and Exit in 4 years as maximum. Nasdaq Pre-IPOs preferred (3 years as maximum to exit).
Outstanding Teams: Experienced leadership with a track record of success.
Building truly differentiated Science with global impact: Significant unmet medical needs at an Agnostic Stage (preclinical – commercialization), with a clear and capital-efficient regulatory pathway. Strong and established IP position.
Diversified pipeline with multiple “shots on goal” with hints of human efficacy or data in patients preferred, In large addressable Market.
Exit Engineered: Relatively short timeline to value inflection. Indications and disease areas that have large-pharma partnership interest.
Second Focus: we will look also outside of therapeutic drug development and evaluate med-device and diagnostics but only if the technology is a paradigm shift or if the team has a significant track record of success.